🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with figures suggesting in excess of 82 million instances annually. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Approval

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in close succession. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Worldwide Availability

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The study included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have voiced optimism. Having a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.